Marinus Pharmaceuticals Says It Is On Track To Achieve Full Year 2024 ZTALMY Net Product Revenue Guidance Of Between $33M And $35M
Portfolio Pulse from Benzinga Newsdesk
Marinus Pharmaceuticals announced that it is on track to achieve its full-year 2024 net product revenue guidance for ZTALMY, estimated to be between $33 million and $35 million.
August 13, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Marinus Pharmaceuticals is on track to achieve its full-year 2024 net product revenue guidance for ZTALMY, estimated to be between $33 million and $35 million.
The confirmation of meeting revenue guidance is a positive indicator for investors, suggesting that the company is performing as expected. This can boost investor confidence and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100